Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon S Lynch

Showing results (1-10 of 176) with videos related to

Pageof 18
Sort By:
Expert Opinion on Emerging Drugs|December 3, 2008
Update on emerging drugs for sarcopenia - age-related muscle wastingGordon S Lynch
Expert Opinion on Emerging Drugs|December 2, 2004
Emerging drugs for sarcopenia: age-related muscle wastingGordon S Lynch
Clinical and Experimental Pharmacology & Physiology|August 10, 2004
Role of contraction-induced injury in the mechanisms of muscle damage in muscular dystrophyGordon S Lynch
Expert Opinion on Pharmacotherapy|May 13, 2022
Identifying the challenges for successful pharmacotherapeutic management of sarcopeniaGordon S Lynch
Regenerative Medicine|October 8, 2025
Translational progress in the development of pharmacotherapies for Duchenne muscular dystrophyKristy Swiderski, Gordon S Lynch
American Journal of Physiology. Cell Physiology|July 14, 2021
Murine models of Duchenne muscular dystrophy: is there a best model?Kristy Swiderski, Gordon S Lynch
Meat Science|June 27, 2018
Dietary meat and protection against sarcopeniaGordon S Lynch, René Koopman
Expert Opinion on Pharmacotherapy|May 24, 2019
Current pharmacotherapies for sarcopeniaJustin P Hardee, Gordon S Lynch
Pharmacology & Therapeutics|October 7, 2008
The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wastingJames G Ryall, Gordon S Lynch
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2008
Plasmid-based gene transfer in mouse skeletal muscle by electroporationJonathan D Schertzer, Gordon S Lynch
Pageof 18

Showing results (1-10 of 176) with videos related to

Sort By:
Pageof 18
Expert Opinion on Emerging Drugs|December 3, 2008
Update on emerging drugs for sarcopenia - age-related muscle wastingGordon S Lynch
Expert Opinion on Emerging Drugs|December 2, 2004
Emerging drugs for sarcopenia: age-related muscle wastingGordon S Lynch
Clinical and Experimental Pharmacology & Physiology|August 10, 2004
Role of contraction-induced injury in the mechanisms of muscle damage in muscular dystrophyGordon S Lynch
Expert Opinion on Pharmacotherapy|May 13, 2022
Identifying the challenges for successful pharmacotherapeutic management of sarcopeniaGordon S Lynch
Regenerative Medicine|October 8, 2025
Translational progress in the development of pharmacotherapies for Duchenne muscular dystrophyKristy Swiderski, Gordon S Lynch
American Journal of Physiology. Cell Physiology|July 14, 2021
Murine models of Duchenne muscular dystrophy: is there a best model?Kristy Swiderski, Gordon S Lynch
Meat Science|June 27, 2018
Dietary meat and protection against sarcopeniaGordon S Lynch, René Koopman
Expert Opinion on Pharmacotherapy|May 24, 2019
Current pharmacotherapies for sarcopeniaJustin P Hardee, Gordon S Lynch
Pharmacology & Therapeutics|October 7, 2008
The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wastingJames G Ryall, Gordon S Lynch
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2008
Plasmid-based gene transfer in mouse skeletal muscle by electroporationJonathan D Schertzer, Gordon S Lynch
Pageof 18